Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.

Date publication

décembre 2016

Journal

Journal of hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27469901

Résumé

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction.

Référence

J. Hepatol.. 2016 Dec;65(6):1140-1147